|
Late Stage Preclinical Projects |
Paul Finnegan |
Development of AB-110: genetically-modified endothelial cells plus expanded cord blood hematopoietic stem cells as a transplantation therapy |
$3,797,117 |
|
Clinical Trial Stage Projects |
Edward Kavalerchik |
AB-110-001 Phase 1b Trial and Related Activities to Support Clinical Development of AB-110 |
$5,000,000 |
|
Clinical Trial Stage Projects |
Edward Kavalerchik |
AB-205-001 Phase 1b Trial and Related Activities to Support Clinical Development of AB-205 |
$6,192,579 |
|
Clinical Trial Stage Projects |
Paul Finnegan |
AB-205-301 Phase 3 Trial and Related Activities to Support Clinical Development of AB-205 |
$15,000,000 |
